Gliomas are a heterogeneous group of primary tumors and have recently undergone improved classification with molecular markers in the new 2016 WHO classification. I will present the molecular marker data from prospective NRG trials (RTOG 0424 and 9802) performed by the Chakravarti lab. Our data will help improve the prognostic classification of low grade gliomas.
Dr. Joshua D. Palmer is an academic radiation oncologist, specializing in central nervous system and pediatric tumors. He has published over 50 peer-reviewed journal articles, abstracts and book chapters related to brain and spine tumors. He has received numerous clinical and research awards including the post-graduate research award from the Alpha Omega Alpha Society to study glioblastoma and the American Society of Clinical Oncology 2015 Conquer Cancer Foundation Oncology Trainee award. He is a Co-PI on two national brain metastasis trials in the RTOG/NRG and ALLIANCE. His research focus includes translational oncology, biomarker discovery, and dietary effect on cancer therapy.
